GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

GlaxoSmithKline Pharmaceuticals reports a 12% increase in net profit to Rs 279 crore for the June quarter despite a slight ...

Net Sales at Rs 804.83 crore in June 2025 down 0.76% from Rs. 811.00 crore in June 2024. Quarterly Net Profit at Rs. 204.70 ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

GlaxoSmithKline (GSK-0.81%) has confirmed plans to separate its consumer and pharmaceutical business units. However, an activist investor appears to want the big drugmaker to take more drastic ...

GlaxoSmithKline's chief executive officer said in an email to the company’s employees that Slaoui’s name would be removed from its research and development facility in Rockville, Md.

July 14, 2010 -- In the face of mounting evidence that GlaxoSmithKline withheld important safety data on their controversial drug Avandia, some doctors are abandoning use of this diabetes treatment.

NEW YORK -- GlaxoSmithKline PLC pulled its controversial Lyme disease vaccine off the market Tuesday, citing plummeting sales -- a move supported by sufferers of the tick-borne disease as well as ...

A vaccine invented at drug giant GlaxoSmithKline and funded in part by the Bill & Melinda Gates Foundation cut the rate of malaria infection in small children roughly in half, providing real hope ...

GlaxoSmithKline is accused in a lawsuit of using threats to block generic competition to its $2-billion-a-year antibiotic Augmentin after a U.S. judge eliminated the drug's patent protection.